Therapeutically targeting TRIB2 in ESCC also has other potential advantages: (1) TRIB2 was critical for the maintenance of CSC properties and their renewal ability, thus TRIB2 disruption would eradicate CSCs and restore radiosensitivity. This evidence concerns the gene TRIB2 and esophageal squamous cell carcinoma.